With over 0.16 million Freeline Therapeutics Holdings plc (FRLN) shares trading Friday and a closing price of $0.52 on the day, the dollar volume was approximately $82969.64. The shares have shown a negative half year performance of -32.23% and its price on 01/13/23 gained nearly 1.96%. Currently, there are 64.98M common shares owned by the public and among those 34.74M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for FRLN have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $15.00 and a low of $2.00. The average price target is 89.6% above its recent price level and an upside to the estimated low will see the stock gain 74.0% over that period. But an upside of 96.53% will see the stock hit the forecast high price target while median target price for the stock is $3.00.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The top 3 mutual fund holders in Freeline Therapeutics Holdings plc are Eventide Healthcare & Life Scienc, Harbor Disruptive Innovation Fund, and Federated Hermes Prudent Bear Fun. Eventide Healthcare & Life Scienc owns 4.72 million shares of the company’s stock, all valued at over $2.24 million. Harbor Disruptive Innovation Fund sold 2768.0 shares to see its total holdings shrink to 0.12 million shares valued at over $58840.0 and representing 0.20% of the shares outstanding. Federated Hermes Prudent Bear Fun now owns shares totaling to 0.10% of the shares outstanding.
Shares of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) opened at $0.525, up $0.02 from a prior closing price of $0.51. However, the script later moved the day high at 0.5389, up 1.96%. The company’s stock has a 5-day price change of 5.18% and -20.01% over the past three months. FRLN shares are trading 9.45% year to date (YTD), with the 12-month market performance down to -64.63% lower. It has a 12-month low price of $0.46 and touched a high of $1.54 over the same period. FRLN has an average intraday trading volume of 34.15K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.01%, -11.66%, and -33.40% respectively.
Institutional ownership of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) shares accounts for 58.40% of the company’s 64.98M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $33.10M. The earnings-per-share (ttm) stands at -$2.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.75% over the week and 11.72% over the month.
Analysts forecast that Freeline Therapeutics Holdings plc (FRLN) will achieve an EPS of -$0.44 for the current quarter, -$0.37 for the next quarter and -$1.49 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.51 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was -$0.86 a year ago. Earnings per share for the fiscal year are expected to decrease by -46.40%, and 48.00% over the next financial year.
JP Morgan was of a view on August 17, 2021 that the stock is Neutral, while H.C. Wainwright gave the stock Buy rating on May 19, 2021, issuing a price target of $30. Guggenheim on their part issued Buy rating on May 06, 2021.
